Log In
Print
BCIQ
Print
Print this Print this
 

ABT-450 plus ritonavir/ombitasvir (ABT-267)/dasabuvir (ABT-333) (3 direct-acting-antiviral (3D) regimen)

Also known as: 3-DAA combination

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionABT-450 plus ritonavir, ABT-267 and ABT-333 triple combination therapy
Molecular Target HCV NS3/4A protease complex ; HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor; HCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 1 infection; Treat HCV genotype 1 infection in cirrhotic patients; Treat HCV genotype 1 infection in treatment-experienced patients with no evidence of liver cirrhosis; Treat HCV genotype 1 infection in treatment-naive patients with no evidence of liver cirrhosis; Treat HCV genotype 1a infection in treatment-naive patients with no evidence of liver cirrhosis; Treat HCV genotype 1b infection in treatment-experienced patients with no evidence of liver cirrhosis; Treat HCV genotype 1b infection in treatment-naive patients; Treat HCV genotype 1b infection in treatment-naive patients with no evidence of liver cirrhosis; Treat HCV genotype 2 infection in treatment-naive patients
Regulatory Designation

U.S. - Breakthrough Therapy (Treat HCV genotype 1 infection)

Partner

Enanta Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today